Jeffries Global Healthcare Conference in London - SUTRO BIOPHARMA INC
All right. Welcome, everyone, to 2026 Jefferies Global Healthcare Conference. My name is Roger Song, Senior Analyst, Kavasimika Biotech. It is my pleasure to have a fireside chat with Su Cho. And then we have Jane and Jonathan join us. Jane, CEO, will give us a brief overview of the company and then join us for our fireside chat. Jane. Thanks, Roger, for the introduction. Thank you all for joining us for this presentation, this mini-presentation before we get into a discussion. I appreciate the opportunity to share the new story for Sutro and give you an update on our pipeline. I will be making forward-looking statements. And, you know, when we did this pivot last March, we actually committed to having three programs into the clinic in three years. We're actually on track to deliver three programs into the clinic in two years. A lot of acceleration of our pipeline and really making us transforming our business from a discovery platform company into a clinical development company is what we're striving to do. Now, when we looked at doing this pivot last March, we were looking at what does the landscape look like? uh companies were moving from the first generation mti payload microtubulin payload to a topo adc payload and i think all of last year everybody wanted a topol adc but today uh the biggest buzz whether you're whether you went to esmo or world adc was about what's next you know what's what's going to overcome resistance to all the topo payload adcs in the clinic and we back last march had already thought about this and that is why by design we actually have this pipeline that have two targets for single payload adcs tissue factor and integrin beta 6 but these programs are meant to validate the platform so that we can achieve far less neutropenia cytopenia rates upon which you can then safely combine dual payloads triple payloads i won't get into those just yet but that is what's really exciting about the platform now we pick two complex targets that are not easily made in the conventional ADC technologies. Tissue factor and integrin beta-6 are expressed and involved in normal process as it is in cancer process and cancer cells. So we know with our sophisticated engineering that we can actually balance the safety and the efficacy well for these two targets, be best in class, validate the platform, and then move quickly into a dual payload format, which then can overcome resistance to any single payload ADC and any target under the sun. So this is a really bold ambition for our company. Now, I spoke to our unique proprietary cell-free technology. The beauty of this is that we get to optimize every component of an ADC, whether it's the antibody, the linker, and the payload. We've optimized our linker strategy to a beta-glucuronidase linker. Ninety percent of the conventional ADCs use a val-al-aval-sit-cathepsin-B linker, but the limitation on that is that it is cleaved in bone marrow or normal tissue, which then leads to the cytopenias. By optimizing our beta-glucuronidaze linker that gets cleaved into the tumor, it's cleaved by the beta-grucurinidase enzyme within the lysosome of cancer cells and actually helps us deliver the payload to the destination, which is the cancer cells over normal cells. In addition, we use these non-natural amino acids that actually help us do site selection. So we actually are not limited by cysteine conjugation, which most of the ADC companies actually conjugate their linker payloads to. And we can actually find the pockets where we can almost bury these linker payloads so that they are not easily cleaved off. And that leads to a highly stable program that then allows us to maximize the therapeutic window for these programs, even though these targets are on normal cells as well as cancer cells. And so this is really something that we're very excited about proving this point with our technology. So let's get into stroke four. we've already in just seven months time and we're moving very quickly in this pivot I would say we're doing faster than China on the clinical development plans and we in just 7 months we we shared our data from early activity as well as our tolerability and safety profile which includes our PK now what's really special about the clinical activity seen so early on is that in seven months you don't actually see these kinds of activities. In fact, tissue factor, the approved tissue factor ADC that's on the market today in cervical cancer only saw one response rate in cervical cancer in their late line phase one trial. The whole idea here for us is to actually go beyond, beyond the two milligram per kilogram dose, and now we're dosing at three to four milligrams, so it's 50 to 100% higher than TIVDAC, the approved ADC, and that delivering that much more punch in terms of potency gets us to actually benefiting and showing activity beyond cervical cancer. And that was our initial strategy to begin with. And now we're seeing early activity come in three different tumors, pancreatic, head and neck, and lung cancer in a U.S. heavily pretreated patient population. I want to make sure that people really take note of that because there's questions on data coming out of China, especially when they don't have access to irinotecan, and they don't have access to innovation. So these are earlier, less heavily treated patient population, whereas in the U.S., there is no question. These patients are third line, fourth line, fifth line, seventh line even, and these are heavily pretreated. A hundred percent of our patients back in this data cohort in August had a hundred percent of treatment with irinotecan in PDAC and CRC, and some of these patients had more than one exposure to irinotican. So seeing activity in this type of patient population is really encouraging. On the safety side, we're seeing limited AEs, mostly grade 1 and grade 2, and really limited heme tox as well as tissue-related target tox, and discontinuations are also very low. One thing to note is a very long half-life of seven days, and the fact that we maintain a 98% DAR-8 configuration for our ADC which means that it's not releasing prematurely the link or payload. Next steps for the program is a more complete data set on the efficacy side of things. In the first half of 27, we'll also be initiating our dose expansion in an earlier line patient population. For stroke 4, this is really what we are very striking, this PK profile. I would challenge anyone to go out there and compare our PK to any other competitive ADC out there. What normally happens, you'll see the solid line of ADCs, which leads to increased exposure at every single dose, and then free payload exposure, which is minimized. And most of the time when you dose an ADC, you see a spike in the free payload that goes north of that, much north of the ADC exposure, and then clears out. What we've designed is we've removed the spike, and that actually lets us mitigate for free payload closure in the circulation, which then reduces the neutropenia and the cytopenias. Let's go into STRO6. STRO 6 is a really exciting target, highly expressed also in lung cancer, head and neck. And despite the Pfizer-MIS, it was a different payload. And so we're very excited about this program, which shows really deep responses across squamous and non-squamous. And this target is expressed in all segments of lung cancer. Whether it be wild type and EGFR, squamous, non-squamous, small cell, non small cell. And I would say 80% of the design for Stro4 and Stro6 are the same. So we would expect to replicate the PK that we just saw in Stro4 into Stro6, which gives us a best-in-class program for Stro6. And obviously you know that lung cancer is not a small opportunity. And then for our initial Phase I schema here, you'll note that we're including a basket of tumors that express integrin beta-6. We're also starting at a higher dose at 1.5 milligram per kilogram than we did for Strophor. Now that we understand where the therapeutic window is, that we could actually get to that antitumor activity dose sooner than with Strophour. Initial data for Strophe 6, we also have guided for second half of 27. This gets to the exciting future of the ADC landscape. You can only do this when you have a technology as unique and special. And it's not about just creating Me Too ADCs. We're not going to China and actually buying them and bringing them to the U.S. We are actually developing, innovating them in-house. The dual payloads is Sutro is what's uniquely positioned to do. Why? Because, one, we have since last year been developing new payloads. We have the tubulins, the DDRIs, the IOs. And we also have a new class of cytotoxic payloads we have not disclosed just yet. And we can tailor and fine-tune the ratios of these payloads. The safety margin on dual payloads is much smaller than single payloads, so you have to be very careful to be able to deliver them effectively. And the ability to fine- tune these ratios, whether it's 1 to 2, 1 plus 3, 8 plus 2, so forth, is not an easy thing when you're limited by conventional ADC technology. And this actually gets us to the safety dose. We're now dosing our PTK7 dual payload as high as 25 milligram per kilogram, which is equivalent to a straight-up DAR8 exit T-can. So that is really telling you that we have a higher safety window with our dual payload programs that go into the clinic. 227, I would also want to clarify, is a DAR8. So it's not only a dual payload, but it's a DAR-8, DAR-10, 8 exotecans, 2 MMAEs. So this is we're dialing up the DAR to drive even more potency while achieving the safety window. And here you see two models where we actually re-challenged tumor models, PDX tumor models that have progressed and been resistant to either an MTI payload in ovarian and re-challenged that with another MTI-ADC, and you see that the dual payload is more effective there in driving deeper response and also followed by a topo-ADCs-resistant model in breast cancer. And here you see 227 actually driving much deeper responses there as well. So in terms of all the execution from the Sutro team the past year and a half, we now have achieved two programs already in the clinic, One soon to get into the clinic. Our PTK7 IND is on track for later this year, early into the clinic next year. And that leaves a lot of catalysts for 2027 from a data standpoint. And we're very excited to see how the pipeline emerges and how we can shape the future of the ADC field moving forward. Thank you. All right. So I think one key highlight I don't want to lost on us is the the renal T-can expose the patient. So the last data says 100% is exposed to a renal t-can. Okay, so one is, what are the key drivers for you, your ADC can be able to do that? You know, X-T-can, the malpotent payload, and then maybe some of the antibodies are different, so that's number one. Number two is, how do you expect from other, you know, ADC, you now, tissue factor ADC they can do if they enroll the patient with prior irinotecan? So I think to answer the question, irinotecan and topo payloads are pretty much the same payload class. And so there is this thinking that, you know, irinotican-exposed patients would have reduced sensitivity to a topo ADC because it's kind of the same class. And what's impressive about the Stroke4 data is that we are seeing clinical activity in patients who have received irinOTecan not just once, but even twice, and so that's really something. If you look at competitive data sets, even for RevMed and other companies, a lot of responses happen in the second and third line, but it also falls off the cliff when it comes to fourth, fifth, sixth, seventh line, because these patients, unfortunately, pancreatic is a hard disease. It progresses really fast, and that's what's so really encouraging about our program and our efficacy thus far, that we're seeing that these patients continue to get responses, and that's a good thing for patients. In terms of other tissue factors being able to achieve the kind of responses we're achieving, it really depends on the, it's not only about the target, but it's also about the payload and kind of the DAR level that they're using, and this is all different based on different competitive products. In just seven months, we shared our early look in the data. Some competitive programs have been in the clinic for two and a half years, and we haven't seen any data there, and I'm very curious to learn what that could be, but I think for us, we're excited about the program. Anything else you want to add there, Jonathan? Yeah, absolutely. I mean, it's been exciting for us to see responses in Orinatican pre-treated patients, and мы recognize the need now to look at Orinatican naive patients, and we're addressing that currently, but that takes longer because you have to work with more specialist investigators, and they want to see the early data before they commit their patients. but that'll be to come. Yeah, makes sense. I think Jane commented earlier, you're faster than China. So for China's speed with the U.S. innovation, that's a very rare combination right now. Yeah. Awesome. All right, so and then you will have data updates in first half next year. I think that will be a very, very important data set for you to move forward. And then you must absolutely pay attention. So what do you want to achieve in that data set? Longer follow-up, maybe more patient number in certain tumor type, and then what's the efficacy level you want to really see? We want to achieve all of those things. Yeah, I mean, listen, we're still in a dose escalation, dose finding part of the phase one, and it's really encouraging to see these early signals of activity. But I think, you know, what we want to do is we want to get to a robust sample of patients. We reported about 49 patients mid-year, and people were wondering why we didn't share more on the efficacy side of things. But when you're looking at 49 patients and you have to divide that by five different doses and eight different tumor types we've included in the trial, you end up getting to a small N. And one out of three, two out of four is not really meaningful in this marketplace. Now, in our dose escalation, we do have backfill cohorts. Now that we're getting to the optimized dose, It's all about getting, enriching for those patients to come in, and, you know, each backfill has about a target end size of about 10, 12 patients, right? So it's not like your dose expansion trial where you pick one indication, one dose, and you have 30 to 40 patients in there. We're still in dose escalation. So I want to be clear in the expectation we're setting. We're going to have, like, maybe 10 to 12 patients in a certain optimized dose level in a specific indication where we're seeing activity. That's what we'd like to see. And we'd to see, you know, how the drug is working amongst those patients. Now, I will also say we're still in that heavily patient-treated population. It's not a second, third-line patient population. So the bar in which you want to compare is just kind of different, right? Every time patients progress from second line to third line or third line to fourth line, they actually, the performance of the patients actually themselves reduced by 30 to 50 percent. So you kind of have to understand what line of therapy, we don't want to do an apples to bananas comparison, we want to an apples to apples comparison. But I would say, even if we get to this later line, you know, cohort, and we are able to see competitive responses, clinical activity in this heavier line patient population than and what we see in competitive data sets out there, that will be a really noteworthy data set for the company. Anything to add there? Yeah, I mean, the other thing is that you never stop learning about tolerability and safety. The more patients you put on, the longer you follow them up, the more you learn. And you have to remember that with our mid-year data release, we saw low levels of AEs generally. It's a very well-tolerated drug from what we've seen, and we really like that. We've seen some on-target TOPs. We saw some stomatitis, which we think is target related in the context of this asset, plus some ocular tox. But you also have to remember that we use no mitigation strategies. We wanted to see what the true profile of any ocular and stomatitis AEs was so that we know where we are. And then when we introduce the mitigation, remembering, again, the effects, the impact of mitigation in the ELAHIR and TIVDAC programs, it makes a big difference. And so we've been pleased with that mitigation. It already looks manageable. And so, we have the option of adding mitigation and improving it further. The platform tox, pleasingly, has been very low. And this reads through to the rest of the platform and will particularly have an impact on the dual payload program that's to come. Got it. You know, you emphasize, you know, all the efficacy and the safety, the benchmark makes sense. And then also the speed, right? I think now I probably will ask too much. Will this data set will help you to really design or at least have some preliminary regulatory discussion to talk about the pivotal plan? Yes, I think it will. I think the numbers will be there that we should open a conversation because, you know, you have to move quickly. And, you Know, it takes time to plan a pivotal study. And the sooner you get the regulators on board with your development plan, the better. and so you know once you have an active drug those conversations need to start got okay oh six another data set we're gonna see it second half so you mentioned the fighter recently I said a bit surprised in the bites mm and he I saw in a different any other thing you want to differentiate from them and then how your confidence level didn't change on you know I don't know if it were increased by at least what's your current confidence level for the first data set will seem very meaningful. Maybe I'll start and then pass it to you, Jonathan. I would say, based on sort of the activity we're seeing with STRO4, mind you, lung and head and neck are not treated with irinotecan, so it kind of gives us an indication as to irinotecan-naive patients, to some extent, and a different indication how those patients would respond, and I'm encouraged by that. So, you know, so that helps us. It's the same link or payload sites of conjugation with one program to the next. And so I think that we could expect to see similar sort of activity there with STROS-6. STROS 6, with the target being a little bit different there, to me what's really encouraging about STROS6 and integrin beta-6 is the fact that it is expressed so widely across lung and head and neck. You know, there's still, even though there's a lot of competition in lung cancer today, There is pockets of lung cancers or segments of lung cancer that is still very high on met need, whether you talk about squamous or even small cell after the first line therapy. And so there's lots of still opportunity for driving benefit. And the thing about it is our payload, not every topo payload is the same. I would say, you know, I would, I'm really excited about our, we chose the ExaTcan most potent topopayload, which is more potent than the Belotekin-DAR8 that's used in SAC-TMT, as well as the Derox-Tekin DAR4 that's using in Datraway. And so why would I expect this payload to be any less effective in lung cancer? Yeah. Yeah. I mean, we've, you know, we're continually reviewing how we're conducting our studies. And, you Know, we recognize now that even with early data releases, you've got to have activity, really to catch the world's eye. And so with STRO6, especially because many of the two lead indications, head and neck and lung cancer, are indications where topisomerase inhibitors aren't typically used, we feel we can trim the indication basket once we get towards active dose levels to only include those tumor types so that every patient is potentially informative, not only for safety but also informative for early signs of anti-tumor activity because we want to try and get to sort of uncover the response signals as early as we can, basically to try to keep up with expectations. Excellent. Okay, last two, three minutes. Dual payload ADC, I think that's a field if everyone talks about it because we know the resistance and we know we want further increase the therapy window. So you choose AMMAE plus top one and then six plus, you know, two, two. So why you choose that? And then what's the preclinical support you choose? Any other ratio you think makes sense? Yeah, so I think combination chemotherapy is the standard of care for most solid tumor indications. And I think we chose the topo plus the MMAE combination first because it is the most validated payloads out there. We know what to expect and what we'll be looking for from a safety perspective with the combination. And the overlapping myelosuppression is what we'd be looking for. Now, if we can sustain and maintain the superior PK profile that we demonstrated already with STRO4 and actually show that we can minimize free payload for the exotecan but also minimize the free payload for the MMAE, then that will be very game-changing for what's possible in terms of dual payloads. That is not an easy thing to do with straight-up conventional ADC technology and conjugation. So for us, picking the most validated payloads, at the same time, we do have a collaboration with Astellas that actually has two ongoing IADC dual payload programs, which combine a sting agonist with an exotecan payload, and these are two different modalities, a little bit higher risk because sting is associated with some immune, you know, sort of reactions, but at the same time, no other company I know of actually has almost three programs of a dual payload in the clinic at this point, and so for a small company like ours to be executing with so many clinical programs is actually a very, you know, a lot of value there. Anything you want to talk about? Yeah, I mean, I agree, Jane. I mean I think, Roger, you also touched on the critical issue of ratio. I mean ideally, in an ideal world, you want to see no platform tox and you obviously are going to dose the tox and you wantto make sure that the tox you see is target tox. With two different payloads, you need to get the ratio right so that you don't hit target tox with one payload before the others reach an effective level of exposure. So we've done an enormous amount of preclinical work, and again, it speaks to the Sutro platform, which is completely tunable in terms of developing ratios. By putting different numbers of non-natural amino acids into the sequence, you can choose what the ratio is going to be, and we think that will be differentiating. And I would say we did do the bake-off, right? We did the bake off of A plus 4, A plus 2, 4 plus 4. And where we landed was to optimize both for safety and efficacy. And so this is something we can really give Sutro a competitive advantage to be able to do this up front and then understand what's the optimized format moving forward. Now, I know other companies also have an 8 plus 2 format for ExaTcan and MMAE, but some of their ExaTCan payloads can't get dosed higher than 1.6 or 2. That is not going to be an easy thing for them to manage the ratios. And by the way, you are not limited by the dollar number. It's not that 10. It's your maximum, right? Yeah, there are some payloads that we're working on, like the ATRI payloads, which will require us to dial up the DAR even further than, like, a straight-up DAR-8. And so that, again, we have made ADCs with DAR-16 that doesn't compromise the PK. So an ability to be able to dial-up the DAR that significantly is not an easy thing to do, and we've been able to achieve that with our platform. Excellent. Thank you so much, Jane, Jonathan. Thank you. Thank you, everyone. Thanks. Thank you.
- Company
- SUTRO BIOPHARMA INC
- Keywords
- SUTRO BIOPHARMA INC